UA106771C2 - Моноклональні антитіла до прогастрину та їх використання - Google Patents
Моноклональні антитіла до прогастрину та їх використанняInfo
- Publication number
- UA106771C2 UA106771C2 UAA201205759A UAA201205759A UA106771C2 UA 106771 C2 UA106771 C2 UA 106771C2 UA A201205759 A UAA201205759 A UA A201205759A UA A201205759 A UAA201205759 A UA A201205759A UA 106771 C2 UA106771 C2 UA 106771C2
- Authority
- UA
- Ukraine
- Prior art keywords
- monoclonal antibodies
- progastrin
- methods
- application
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Abstract
Цей опис винаходу стосується моноклональних антитіл до прогастрину, його фрагментів, композицій, які включають моноклональні антитіла до прогастрину, а також способи виготовлення і використання моноклональних антитіл до прогастрину та їх композицій. Цей опис винаходу стосується способів лікування колоректального раку моноклональними антитілами до прогастрину і композиціями, що включають моноклональні антитіла до прогастрину або їх фрагменти. Цей опис винаходу також стосується способів, які включають визначення прогастрину, у тому числі способів діагностування колоректального раку і способів контролю ефективності протиракової терапії у суб'єктів, які страждають колоректальним раком.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25262509P | 2009-10-16 | 2009-10-16 | |
PCT/EP2010/006329 WO2011045080A2 (en) | 2009-10-16 | 2010-10-15 | Monoclonal antibodies to progastrin and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
UA106771C2 true UA106771C2 (uk) | 2014-10-10 |
Family
ID=43086711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201205759A UA106771C2 (uk) | 2009-10-16 | 2010-10-15 | Моноклональні антитіла до прогастрину та їх використання |
Country Status (40)
Country | Link |
---|---|
US (7) | US9611320B2 (uk) |
EP (2) | EP3421493B1 (uk) |
JP (3) | JP5985987B2 (uk) |
KR (2) | KR20120091221A (uk) |
CN (2) | CN104628857A (uk) |
AP (1) | AP2012006262A0 (uk) |
AR (1) | AR078659A1 (uk) |
AU (1) | AU2010306119A1 (uk) |
CA (1) | CA2777691C (uk) |
CL (1) | CL2012000914A1 (uk) |
CR (1) | CR20120184A (uk) |
CU (1) | CU24196B1 (uk) |
CY (1) | CY1120913T1 (uk) |
DK (1) | DK2488551T3 (uk) |
EA (2) | EA201791876A1 (uk) |
EC (1) | ECSP12011796A (uk) |
ES (1) | ES2690943T3 (uk) |
GE (1) | GEP201706604B (uk) |
GT (1) | GT201200114A (uk) |
HK (1) | HK1178183A1 (uk) |
HN (1) | HN2012000708A (uk) |
HR (1) | HRP20181645T1 (uk) |
IL (2) | IL219019B (uk) |
IN (1) | IN2012DN03348A (uk) |
LT (1) | LT2488551T (uk) |
MA (1) | MA33747B1 (uk) |
MX (1) | MX351635B (uk) |
NI (1) | NI201200054A (uk) |
NZ (2) | NZ599971A (uk) |
PE (1) | PE20121649A1 (uk) |
PL (1) | PL2488551T3 (uk) |
PT (1) | PT2488551T (uk) |
RS (1) | RS57966B1 (uk) |
SG (1) | SG10201704933PA (uk) |
SI (1) | SI2488551T1 (uk) |
TN (1) | TN2012000159A1 (uk) |
TW (1) | TWI537002B (uk) |
UA (1) | UA106771C2 (uk) |
WO (1) | WO2011045080A2 (uk) |
ZA (1) | ZA201202642B (uk) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
WO2008076454A1 (en) | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
AR078659A1 (es) * | 2009-10-16 | 2011-11-23 | Biorealites S A | Anticuerpos monoclonales contra progastrina humana y sus usos |
US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
BR112012024036B1 (pt) * | 2010-03-24 | 2020-03-03 | Les Laboratoires Servier | Profilaxia de câncer colorretal e gastrointestinal |
US10533050B2 (en) * | 2010-07-26 | 2020-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and compositions for liver cancer therapy |
US8785603B2 (en) * | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
US9410955B2 (en) | 2011-06-01 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for predicting the risk of developing a colonic neoplasia |
EP3708189B1 (en) | 2013-07-05 | 2023-11-29 | University of Washington through its Center for Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
MX2016013686A (es) * | 2014-04-18 | 2017-03-31 | Univ New York State Res Found | Anticuerpos de antigeno anti-tf humanizado. |
US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
WO2016066671A1 (en) | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
EP3349768A4 (en) * | 2015-09-15 | 2019-01-23 | The Scripps Research Institute | ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF |
ES2901602T3 (es) * | 2015-12-31 | 2022-03-23 | Progastrine Et Cancers S A R L | Composiciones y métodos para detectar y tratar el cáncer ovárico |
BR112018013268A2 (pt) * | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer gástrico |
BR112018013269A2 (pt) * | 2015-12-31 | 2018-12-11 | Syncerus S A R L | composições e métodos para a avaliação do risco de ocorrência do câncer |
EA201992315A1 (ru) * | 2017-03-30 | 2020-03-04 | Прогастрин Э Кансер С.А Р.Л. | Композиции и способы для лечения рака легкого |
KR102351556B1 (ko) * | 2017-03-30 | 2022-01-14 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법 |
ES2920283T3 (es) * | 2017-12-05 | 2022-08-02 | Progastrine Et Cancers S A R L | Terapia de combinación entre un anticuerpo antiprogastrina y la inmunoterapia para tratar el cáncer |
JP7338128B2 (ja) | 2017-12-08 | 2023-09-05 | イー、シー、エス、ビオトラッカー、エス、エー、アール、エル | 癌診断における放射性標識プロガストリン |
WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
US20200400675A1 (en) * | 2018-02-27 | 2020-12-24 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
TWI793238B (zh) * | 2018-12-27 | 2023-02-21 | 偉喬生醫股份有限公司 | 體外檢測生物樣品之胃源性蛋白的方法及套組 |
CN115785273B (zh) * | 2021-09-10 | 2023-10-31 | 东莞市朋志生物科技有限公司 | 一种抗胃蛋白酶原i的抗体及其应用 |
CN117567611A (zh) * | 2023-11-22 | 2024-02-20 | 艾维可生物科技有限公司 | 抗成熟型胃泌素17的单克隆抗体及其应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
CA2580965C (en) | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
WO2007135542A2 (en) * | 2006-05-22 | 2007-11-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Progastrin inhibitors in the treatment of colon cancer |
WO2008076454A1 (en) | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
AR078659A1 (es) * | 2009-10-16 | 2011-11-23 | Biorealites S A | Anticuerpos monoclonales contra progastrina humana y sus usos |
-
2010
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko active Application Filing
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active IP Right Grant
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en active Application Filing
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
-
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
-
2013
- 2013-05-20 HK HK13105899.6A patent/HK1178183A1/zh unknown
-
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
-
2017
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
-
2018
- 2018-10-11 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
-
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
-
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106771C2 (uk) | Моноклональні антитіла до прогастрину та їх використання | |
MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
JO3097B1 (ar) | الأجسام المضادة c-Met | |
PH12014502419A1 (en) | Specific binding proteins and uses thereof | |
NZ599737A (en) | Il-17a antagonists | |
NZ626610A (en) | Antibodies that bind csf1r | |
MY159553A (en) | Detection and treatment of pancreatic, ovarian and other cancers | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
EA201500219A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
MX355849B (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina. | |
UA114277C2 (uk) | Антиангіогенна терапія для лікування раку яєчника | |
MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
NZ611785A (en) | Anti-notch1 antibodies | |
NZ607588A (en) | Antibodies against human TWEAK and uses thereof | |
MX352373B (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
MX347463B (es) | Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf. | |
WO2013149219A3 (en) | Fully human antibodies that bind to vegfr2 | |
MX362497B (es) | Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo. | |
TH133902A (th) | มอนอโคลนัลแอนติบอดีสำหรับโพรแกสตรินและการใช้ประโยชน์ของมอนอโคลนัลแอนติบอดี | |
TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
TH133902B (th) | มอนอโคลนัลแอนติบอดีสำหรับโพรแกสตรินและการใช้ประโชน์ของมอนอโคลนัล แอนติบอดี |